Researchers have developed a new statistical tool called BayesPrism to better understand the complex tumor microenvironment by combining different types of genetic data. While traditional single-cell sequencing provides detailed information, it is often too expensive and technically limited for large patient groups, whereas bulk RNA-seq is widely available but lacks cellular detail. BayesPrism uses a Bayesian strategy to accurately identify the specific types of cells within a tumor and determine their unique gene expression levels. This method has proven more reliable than previous techniques, successfully identifying how different immune cells, such as macrophages and T cells, influence patient survival and cancer progression. By applying this tool to various cancers like glioblastoma and melanoma, the study reveals how malignant cells interact with their surroundings to adapt and grow. Ultimately, this software offers a powerful way to utilize existing medical data to discover new clinical biomarkers and potential targets for therapy.

References:

• Chu, T., Wang, Z., Pe’er, D. et al. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat Cancer 3, 505–517 (2022). doi.org